Novo Nordisk A S repurchased 21,845,000 shares in buyback
Novo Nordisk A S reported accumulated repurchases of 21,845,000 shares for a transaction value of 6,447,270,879 under its share repurchase programme.
What happened
Novo Nordisk A S filed Form 6-K with the SEC on 2026-10-06. The filing reported accumulated repurchases of 21,845,000 shares with a transaction value of 6,447,270,879 under the programme.
On 28 September 2026, 245,000 B shares were repurchased at 253.30 for 62,059,136. On 29 September 2026, 245,000 B shares were repurchased at 252.74 for 61,921,920. On 30 September 2026, 245,000 B shares were repurchased at 250.50 for 61,372,450.
On 1 October 2026, 245,000 B shares were repurchased at 249.50 for 61,126,718. On 2 October 2026, 245,000 B shares were repurchased at 248.77 for 60,948,613. According to the company, the prior accumulated total was 20,620,000 shares with a transaction value of 6,139,842,042.
Form 6-K is a filing submitted to the SEC. B shares are a class of shares in the company, and the transaction value is the total amount paid for the shares listed.
Treasury holding shows how buyback affects share capital
Novo Nordisk owned a total of 50,644,876 B shares of DKK 0.10 as treasury shares. The treasury shares corresponded to 1.1% of the share capital.
This programme was part of the overall share repurchase programme of up to DKK 15 billion. Under the programme initiated 6 May 2026, Novo Nordisk would repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.
A share repurchase means the company buys its own shares and can hold them as treasury shares. Treasury shares are shares held by the company itself and are included in the total share count reported. Share capital is the total number of shares the company has issued.
